Phenylpropanolamine: Difference between revisions
mNo edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Overview of Phenylpropanolamine}} | |||
[[File:Phenylpropanolamine.svg|Phenylpropanolamine|thumb]] | |||
[[File:Phenylpropanolamine molecule ball.png|Phenylpropanolamine molecule ball|thumb]] | |||
[[File:Phenylpropanolamine spacefill.png|Phenylpropanolamine spacefill|thumb]] | |||
'''Phenylpropanolamine''' (PPA) is a [[sympathomimetic]] agent used as a [[decongestant]] and [[appetite suppressant]]. It is a member of the [[phenethylamine]] class and is structurally related to [[ephedrine]] and [[amphetamine]]. | |||
= Phenylpropanolamine | ==Pharmacology== | ||
Phenylpropanolamine acts primarily as an [[alpha-adrenergic receptor]] agonist, leading to vasoconstriction and decreased nasal congestion. It also has some activity as a [[beta-adrenergic receptor]] agonist, which contributes to its effects on appetite suppression. | |||
Phenylpropanolamine | ==Medical Uses== | ||
Phenylpropanolamine was commonly used in over-the-counter cold medications and weight loss products. It was effective in reducing nasal congestion and suppressing appetite. | |||
== | ==Safety and Regulation== | ||
In the early 2000s, concerns about the safety of phenylpropanolamine led to its withdrawal from the market in many countries. Studies indicated an increased risk of [[hemorrhagic stroke]] in women using the drug. As a result, the [[U.S. Food and Drug Administration]] (FDA) issued a public health advisory in 2000, recommending that consumers not use products containing phenylpropanolamine. | |||
==Current Status== | |||
Phenylpropanolamine is no longer available in the United States and many other countries for human use. However, it is still used in veterinary medicine, particularly for the treatment of urinary incontinence in dogs. | |||
Phenylpropanolamine | ==Mechanism of Action== | ||
Phenylpropanolamine works by stimulating the release of [[norepinephrine]] and [[dopamine]] from nerve terminals, which leads to increased adrenergic activity. This results in vasoconstriction and reduced blood flow to the nasal passages, alleviating congestion. | |||
== | ==Side Effects== | ||
Common side effects of phenylpropanolamine include increased heart rate, elevated blood pressure, anxiety, dizziness, and insomnia. Due to its stimulant effects, it can also lead to [[tachycardia]] and [[hypertension]]. | |||
== | ==History== | ||
Phenylpropanolamine was first introduced in the 1930s and became widely used in the 1970s and 1980s. Its popularity declined after safety concerns emerged, leading to regulatory actions in the 1990s and 2000s. | |||
=== | ==Also see== | ||
* [[Ephedrine]] | |||
* [[Pseudoephedrine]] | |||
* [[Amphetamine]] | |||
* [[Sympathomimetic drug]] | |||
* [[Decongestant]] | |||
* | |||
* | |||
[[ | |||
[[ | |||
[[ | |||
[[ | |||
{{stub}} | {{stub}} | ||
[[Category:Sympathomimetic amines]] | |||
[[Category:Decongestants]] | |||
[[Category:Withdrawn drugs]] | |||
Latest revision as of 03:21, 22 March 2025
Overview of Phenylpropanolamine
Phenylpropanolamine (PPA) is a sympathomimetic agent used as a decongestant and appetite suppressant. It is a member of the phenethylamine class and is structurally related to ephedrine and amphetamine.
Pharmacology[edit]
Phenylpropanolamine acts primarily as an alpha-adrenergic receptor agonist, leading to vasoconstriction and decreased nasal congestion. It also has some activity as a beta-adrenergic receptor agonist, which contributes to its effects on appetite suppression.
Medical Uses[edit]
Phenylpropanolamine was commonly used in over-the-counter cold medications and weight loss products. It was effective in reducing nasal congestion and suppressing appetite.
Safety and Regulation[edit]
In the early 2000s, concerns about the safety of phenylpropanolamine led to its withdrawal from the market in many countries. Studies indicated an increased risk of hemorrhagic stroke in women using the drug. As a result, the U.S. Food and Drug Administration (FDA) issued a public health advisory in 2000, recommending that consumers not use products containing phenylpropanolamine.
Current Status[edit]
Phenylpropanolamine is no longer available in the United States and many other countries for human use. However, it is still used in veterinary medicine, particularly for the treatment of urinary incontinence in dogs.
Mechanism of Action[edit]
Phenylpropanolamine works by stimulating the release of norepinephrine and dopamine from nerve terminals, which leads to increased adrenergic activity. This results in vasoconstriction and reduced blood flow to the nasal passages, alleviating congestion.
Side Effects[edit]
Common side effects of phenylpropanolamine include increased heart rate, elevated blood pressure, anxiety, dizziness, and insomnia. Due to its stimulant effects, it can also lead to tachycardia and hypertension.
History[edit]
Phenylpropanolamine was first introduced in the 1930s and became widely used in the 1970s and 1980s. Its popularity declined after safety concerns emerged, leading to regulatory actions in the 1990s and 2000s.
